United States · Bill · HR
H.R. 46 (96th)
Prescription Drug Patent Licensing Act
Introduced
15 January 1979
Last action
—
Status
Referred to House Committee on the Judiciary.
Sponsors
—
Subjects
Discovery layer
Source updated
2 September 2025
Summary
Prescription Drug Patent Licensing Act - Requires that whenever, upon complaint by a qualified applicant for a license under a drug patent, the Federal Trade Commission determines that such license application was not granted and that the price quoted to druggists by the patentee is more than 500 percent of the total cost of production, the Commission shall order the patentee (under penalty of patent cancellation by the Commissioner of Patents) to grant an unrestricted license to any qualified applicant to make, use, and sell such drug. Permits the Commission to delay the issuance of such order for up to five years to provide a fair return on the patentee's invested capital.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
1 official file
Introduced in House
summary · EN · 15 January 1979
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/96th-congress/house-bill/46
- Open data entity: https://api.congress.gov/v3/bill/96/hr/46